Disease Management and Health Outcomes

, Volume 6, Issue 5, pp 279–290 | Cite as

Disease Management by Prevention

The Prospects for Diabetic Retinopathy
Review Article
  • 4 Downloads

Abstract

Diabetic retinopathy is a significant cause of visual loss in developed countries. Data from epidemiological studies and controlled clinical trials have resulted in treatment strategies, which are highly successful in preventing blindness. These strategies involve measures that require both education and compliance of the individual with diabetes mellitus and the education of physicians and paramedical staff who deliver care to these patients. This paper presents the classification of diabetic retinopathy and the treatment strategies, both the preventive measures and the active treatment modalities used for diabetic retinopathy. Persons with diabetes should be invited from the first day of diagnosis to be active partners working towards the prevention of diabetic complications.

The management of patients with diabetes includes essential medical preventive measures such as tight glucose level and blood pressure control and the lowering of serum cholesterol levels to successfully decrease the risk of microvascular complications, namely diabetic retinopathy, neuropathy and nephropathy. Persons with diabetes should also be aware of the importance of screening for diabetic retinopathy and the beneficial effects of timely laser photocoagulation and other surgical interventions.

Keywords

Diabetic Retinopathy Diabetic Macular Oedema Proliferative Diabetic Retinopathy United Kingdom Prospective Diabetes Study Early Treatment Diabetic Retinopathy Study 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: early treatment diabetic retinopathy study report #18. Invest Ophthalmol Vis Sci 1998; 39: 233–52PubMedGoogle Scholar
  2. 2.
    Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report no. 12. Ophthalmology 1991; 98: 823–33Google Scholar
  3. 3.
    Klein BEK, Moss SE, Klein R, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, X: relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991; 98: 1261–5PubMedGoogle Scholar
  4. 4.
    Chew EY, Klein ML, Ferris III FL, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Arch Ophthalmol 1996; 114: 1079–84PubMedCrossRefGoogle Scholar
  5. 5.
    The Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS report no. 1. Arch Ophthalmol 1985; 103: 1796–806CrossRefGoogle Scholar
  6. 6.
    Murphy RP. Management of diabetic retinopathy. Am Fam Physician 1995; 51: 785–96PubMedGoogle Scholar
  7. 7.
    The Diabetic Retinopathy Study Research Group. Four risk factors for severe visual loss in diabetic retinopathy: the third report of the diabetic retinopathy study. Arch Ophthalmol 1979; 97: 654–5CrossRefGoogle Scholar
  8. 8.
    Diabetic Retinopathy Study Group. A modification of the Airlie House classification of diabetic retinopathy. Invest Ophthal Vis Sci 1981; 21: 210–26Google Scholar
  9. 9.
    Fong DS, Ferris FL, Davis MD, et al. Causes of severe visual loss in the Early Treatment Diabetic Retinopathy Study: ETDRS report no. 24. Am J Ophthalmol 1999; 127: 137–41PubMedCrossRefGoogle Scholar
  10. 10.
    Kostraba JN, Klein R, Dorman JS, et al. The epidemiology of diabetes complications study. IV Correlates of diabetic background and proliferative retinopathy. Am J Epidemiol 1991; 133: 381–91PubMedGoogle Scholar
  11. 11.
    Harris MI, Robbins DC. Prevalence of adult onset IDDM in the US populations. Diabetes Care 1994; 17: 1337–40PubMedCrossRefGoogle Scholar
  12. 12.
    Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520–6PubMedCrossRefGoogle Scholar
  13. 13.
    Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527–32PubMedCrossRefGoogle Scholar
  14. 14.
    Klein R, Klein BEK, Moss SE, et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988; 260: 2864–71PubMedCrossRefGoogle Scholar
  15. 15.
    Klein R, Klein BEK, Moss SE, et al. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994; 154: 2169–78PubMedCrossRefGoogle Scholar
  16. 16.
    Lloyd CE, Klein R, Maser RE, et al. The progression of retinopathy over 2 years: the Pittsburgh epidemiology of diabetes complications (EDC) study. J Diab Complications 1995; 3: 140–8CrossRefGoogle Scholar
  17. 17.
    Janka HU, Warram JH, Rand LI, et al. Risk factors for progression of background retinopathy in long-standing IDDM. Diabetes 1989; 38: 460–4PubMedCrossRefGoogle Scholar
  18. 18.
    Teuscher A, Schnell H, Wilson PWF. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 1988; 11: 246–51PubMedCrossRefGoogle Scholar
  19. 19.
    Marshall G, Garg SK, Jackson WE, et al. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology 1993; 100: 1133–9PubMedGoogle Scholar
  20. 20.
    Krolewski AS, Warram JH, Rand LI, et al. Risk of proliferative diabetic retinopathy in juvenile-onset type I diabetes: a 40-year follow-up study. Diabetes Care 1986; 9: 443–552PubMedCrossRefGoogle Scholar
  21. 21.
    Arfken CL, Salicrup AE, Meuer SM, et al. Retinopathy in African Americans and Whites with insulin-dependent diabetes mellitus. Arch Intern Med 1994; 154: 2597–602PubMedCrossRefGoogle Scholar
  22. 22.
    Krolewski AS, Barzilay J, Warram JH, et al. Risk of early-onset proliferative diabetic retinopathy in IDDM is closely related to cardiovascular autonomic neuropathy. Diabetes 1992; 41: 430–7PubMedCrossRefGoogle Scholar
  23. 23.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86CrossRefGoogle Scholar
  24. 24.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol 1995; 113: 36–51CrossRefGoogle Scholar
  25. 25.
    The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposures (HbA1C) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968–83CrossRefGoogle Scholar
  26. 26.
    The Diabetes Control and Complications Trial Research Group. Perspectives in Diabetes. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289–98CrossRefGoogle Scholar
  27. 27.
    Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304–9PubMedCrossRefGoogle Scholar
  28. 28.
    Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Rapid tightening of blood glucose control leads to transient deterioration of retinpathy in insulin-dependent diabetes mellitus: the Oslo Study. BMJ 1985; 290: 811–5PubMedCrossRefGoogle Scholar
  29. 29.
    Kroc Collaborative Study Group. The Kroc Study patients at two years: a report on further retinal changes. Diabetes 1985; 34:39Google Scholar
  30. 30.
    Lauritzen T, Frost-Larsen K, Larsen HW, et al. Steno Study Group. Effect of one year of near-normal blood glucose levels on retinpathy in insulin-dependent diabetics. Lancet 1983; I: 200–4CrossRefGoogle Scholar
  31. 31.
    Klein R, Klein B, Moss S. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996; 124: 90–6PubMedGoogle Scholar
  32. 32.
    Ohkubo Y, Hideke K, Eiichi A, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diab Res Clin Pract 1995; 28: 103–17CrossRefGoogle Scholar
  33. 33.
    UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53CrossRefGoogle Scholar
  34. 34.
    UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65CrossRefGoogle Scholar
  35. 35.
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13CrossRefGoogle Scholar
  36. 36.
    Chaturvedi N, Sjolie AK, Stephen JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28–31PubMedCrossRefGoogle Scholar
  37. 37.
    Fong DS, Segal PP, Myers F, et al. Subretinal fibrosis in diabetic macular edema, ETDRS Report No. 23. Arch Ophthalmol 1997; 115: 873–7PubMedCrossRefGoogle Scholar
  38. 38.
    Ferris FL. How effective are treatments for diabetic retinopathy? JAMA 1993; 269(10): 1290–1PubMedCrossRefGoogle Scholar
  39. 39.
    Brechner RJ, Cowie CC, Howie J, et al. Ophthalmic examination among adults with diagnosed diabetes mellitus. JAMA 1993; 270: 1714–8PubMedCrossRefGoogle Scholar
  40. 40.
    Wang F, Javitt JC. Eye care for elderly Americans with diabetes mellitus. Failures to meet current guidelines. Ophthalmology 1996; 103: 1744–50PubMedGoogle Scholar
  41. 41.
    Diabetes care and research in Europe. The saint vincent declaration. Diabetic Med 1990; 7: 360CrossRefGoogle Scholar
  42. 42.
    Javitt JC, Canner JK, Frank RG, et al. Detecting and treatment retinopathy in patients with type 1 diabetes mellitus. Ophthalmology 1990; 97: 483–95PubMedGoogle Scholar
  43. 43.
    Javitt JC, Aiello LP, Bassi LJ, et al. Detecting and treating retinopathy in patients with type 1 diabetes mellitus: savings associated with improved implementation of current guidelines. Ophthalmology 1991; 98: 1565–74PubMedGoogle Scholar
  44. 44.
    Javitt JC, Aiello LP. Cost-effectives of detecting and treating diabetic retinopathy. Ann Intern Med 1996; 124: 164–9PubMedGoogle Scholar
  45. 45.
    Savolainen EA, Lee AP. Diabetic retinopathy — need and demand for photocoagulation and its cost-effectiveness: evaluation based on services in the United Kingdom. Diabetologia 1982; 23: 138–40PubMedCrossRefGoogle Scholar
  46. 46.
    American Academy of Ophthalmology. Diabetic retinopathy. Preferred practice pattern. San Francisco: American Academy of Ophthalmology, 1998Google Scholar
  47. 47.
    Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20: 735–44PubMedCrossRefGoogle Scholar
  48. 48.
    Hanson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998; 351: 1755–62CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Division of Biometry and EpidemiologyNational Eye Institute/National Institutes of HealthBethesdaUSA

Personalised recommendations